Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 131,754

Document Document Title
WO/2018/148629A3
This invention is generally related to novel compositions and methods for treating or preventing fibrosis, diseases or disorders associated with fibrosis, neurodegeneration, diseases or disorders associated with neurodegeneration and car...  
WO/2018/145553A1
The present disclosure provides co-crystals of a substituted glycine compound and a co-former compound of Formula (I), compositions comprising such, and uses thereof in treating and/or reducing the risk for a neuropsychiatricdisorder (e....  
WO/2018/145216A1
An herbal pharmaceutical compositions of California poppy and methods for the treatment of sleep disorders and dream-related disorders is disclosed. The formulation may be in the form of capsules, tablets, caplets or other oral dosage fo...  
WO/2018/148737A1
The present invention is directed to the use of a 5-HT2A serotonin receptor inverse agonist for the prophylaxis and/or treatment of the symptoms of dementia with Lewy bodies, Parkinson's disease, or a combination thereof in an individual...  
WO/2018/148220A1
Some embodiments herein related to methods, composition, and/or uses for reducing the likelihood of, delaying the onset of, or ameliorating one or more symptoms associated with Rett syndrome or Huntington's disease. Without being limited...  
WO/2018/148509A1
Provided are methods of evaluating an ability of a therapeutic composition to modulate a dopaminergic activity in an organ of a mammalian subject having a dopaminergic disorder. Also provided are methods of assessing and monitoring the p...  
WO/2018/147792A1
The present invention provides the steroid compound 3beta-hydroxy-5alpha- pregnan-20-onefor use in treatment of Tourette's syndrome, obsessive compulsive disorder and/or gambling disorder, as well as methods for treating said disorders a...  
WO/2018/148313A1
Solid formulations comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof, and their use in the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), are provided.  
WO/2018/143806A1
The invention relates to nutritional compositions for infants or toddlers comprising prebiotic fiber and a probiotic bacterium and glutamine for use in accelerating maturation of brain microstructure and accelerating maturation of cognit...  
WO/2018/144441A1
Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) α-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis ...  
WO/2018/144827A1
Methods of treating tinnitus with gaboxadol or a pharmaceutically acceptable salt thereof are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of tinnitus. Methods of treating acute se...  
WO/2018/144551A3
The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging - and their neurol...  
WO/2018/143793A1
The invention relates to nutritional compositions for infants or toddlers comprising prebiotic fiber and a probiotic bacterium and glutamine for use in accelerating maturation of brain microstructure and accelerating maturation of cognit...  
WO/2018/141662A1
The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of ...  
WO/2018/143384A1
Provided is a novel percutaneous absorption type patch containing rotigotine. A percutaneous absorption type patch which comprises a support, a drug-containing layer and a release liner, wherein the drug-containing layer contains rotigot...  
WO/2018/144910A1
The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the prog...  
WO/2018/144981A1
A method of increasing autophagy in a subject, comprising: identifying a subject in need thereof; and administering to the subject a composition that contains small cells that are greater than 2 micrometers and less than 6 micrometers in...  
WO/2018/141886A1
The present invention relates to crystalline brexpiprazole having a particle size distribution (PSD) characterized by a d(90) of 30 μm to 100 μm, by a d(10) of at least 1.0 μm, and by a d(4,3) of at least 15.0 μm. The present inventi...  
WO/2018/145009A1
Provided herein are methods and compositions for treating Huntington's disease. For example, provided are compositions that include DNA oligonucleotides that have targeting specificity for RNA encoding mutant huntingtin protein. When int...  
WO/2018/143893A1
The invention relates to compounds that are useful in the treatment of parkinsonism, such as parkinsonism in connection with Parkinson's disease (PD); dementia with Lewy bodies (DLB); multiple system atrophy (MSA); corticobasal degenerat...  
WO/2018/141661A1
The invention relates to a pharmaceutical patch comprising a Lidocaine constituent and a Diclofenac constituent, wherein the relative weight content ratio of the Lidocaine constituent to the Diclofenac constituent is within the range of ...  
WO/2018/144551A2
The present invention relates to a method of treating or preventing cellular dysfunction and death caused by genetic, degenerative, toxic, traumatic, ischemic, infectious, neoplastic and inflammatory diseases and aging - and their neurol...  
WO/2018/144816A1
The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the ...  
WO/2018/137619A1
The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized...  
WO/2018/140563A1
Provided herein is a method for reducing the likelihood of epileptogenesis in a subject (e.g., a subject at risk thereof), comprising administering to said subject (e.g., a human subject) an effective amount a peptide of Formula I, or a ...  
WO/2018/140799A2
Disclosed herein are compositions and methods for the treatment of non-otic diseases or conditions with Trk receptor agonist compositions and formulations.  
WO/2018/140630A1
The invention provides a compound of formula (I): wherein R1, R2, R3, and R4 are as defined herein, ginsenoside Rg2 of structure (II): or a combination thereof, for use in treating or preventing a condition responsive to the induction of...  
WO/2018/137483A1
A sustained-release nanoparticle for targeting a neurodegenerative disease, a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing and/or treating a neurodegen...  
WO/2018/137627A1
Disclosed are a sustained release composition of aripiprazole and a derivative thereof and a preparation method therefor. The non-solvent preparation raw materials of the sustained release composition comprise aripiprazole and a sparingl...  
WO/2018/137629A1
Disclosed are a sustained release composition and a preparation method therefor. The non-solvent preparation raw materials comprise risperidone, a sparingly water-soluble polymer and a release regulator. The release regulator comprises a...  
WO/2018/137607A1
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase a...  
WO/2018/140799A3
Disclosed herein are compositions and methods for the treatment of non-otic diseases or conditions with Trk receptor agonist compositions and formulations.  
WO/2018/137593A1
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase a...  
WO/2018/140299A1
The present invention provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula (I) for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.  
WO/2018/137630A1
Disclosed are a risperidone sustained release composition and a preparation method therefor. The non-solvent preparation raw materials of the composition comprise risperidone, a sparingly water-soluble polymer and a release regulator. Th...  
WO/2018/138086A1
The present invention relates to bis-heteroaryl compounds of formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, an...  
WO/2018/138358A1
The present invention relates to UPR pathway inhibitors, in particular PERK and IRE-1 A inhibitors for use in the prevention or treatment of neurodevelopmental disorders, such as microcephaly caused by ZIKV.  
WO/2018/138400A3
The present invention relates to a high-yield method for the production of extracts enriched with organosulfur compounds of the S-alkenyl-L-cysteine and S-alkyl-L-cysteine type. Said compounds are obtained from plants of the genus Allium...  
WO/2018/140504A1
The disclosure provides methods for treating a subject suffering from a disease associated with sodium channel activity. The method comprises administering to the subject a therapeutically effective amount of a compound according to Form...  
WO/2018/138709A1
A brain-penetrating composition of amyloid-ß binding peptide is disclosed. This may be useful in the treatment of Alzheimer's disease, for example as a bifunctional molecule, comprising a blood-brain barrier crossing antibody and an amy...  
WO/2018/138389A1
The present invention relates to the use of methylphenidate or any of the salts or derivatives thereof, and to a composition, particularly a pharmaceutical composition containing same, for the production of a drug for the prevention and/...  
WO/2018/140965A1
Neuroinflammation mediated by microglia and infiltrating peripheral immune cells is a major component of stroke pathophysiology. The calcium activated potassium channel KCa3.1 is expressed selectively in the injured CNS by microglia, and...  
WO/2018/139471A1
The present invention relates to a dibenzodiazepine derivative represented by formula (1), which is useful as a therapeutic and/or prophylactic agent for central nervous system diseases, and a pharmaceutically acceptable salt thereof. (I...  
WO/2018/138085A1
The present invention relates to certain bis-heteroaryl compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and metho...  
WO/2018/137573A1
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase a...  
WO/2018/138929A1
Provided are a novel use of 1,2-di-O-galloyl-4,6-O-(S)-hexahydroxydiphenoyl-β-D-glucose (hereinafter abbreviated as "GHG") which is contained in a large amount in purple tea produced in Kenya (scientific name: Camellia sinensis, variet...  
WO/2018/140876A1
Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.  
WO/2018/137618A1
Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.  
WO/2018/137628A1
Disclosed are a sustained release composition of paliperidone and a derivative thereof and a preparation method therefor. The raw materials comprise paliperidone or a paliperidone derivative and a sparingly water-soluble polymer. The sus...  
WO/2018/136710A1
This application provides methods of treating Krabbe disease, for example in an infant. Such methods can include immunosuppressing the patient, for example by administration of a myeloablative regimen, administering an umbilical cord blo...  

Matches 401 - 450 out of 131,754